Literature DB >> 29230662

Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.

Kamaljeet Singh1, Xin He2, Elizabeth T Kalife3, Shahrzad Ehdaivand3, Yihong Wang4, C James Sung3.   

Abstract

PURPOSE: Oncotype Dx (ODx) is a multigene assay that is prognostic and predictive in estrogen receptor (ER) positive early breast cancer. ODx recurrence score (RS) is reported to be histologic grade dependent. Relationship of RS with breast cancer histologic subtypes is unknown. This study was designed to assess the relationship of histologic subtype with RS. Histologic grade dependence of RS was also investigated.
METHODS: Results of consecutive ODx tests (1/2007-7/2016) from two institutions were reviewed. Histologic subtypes (in: Lakhani et al., WHO classification, IARC Press, Lyon, 2012), combined Nottingham histologic grade, age and tumor size were recorded from pathology reports. Univariate and multivariate analysis was performed to investigate the relationship between RS and ODx risk categories and histologic subtypes, grade, age and tumor size.
RESULTS: RS was grade dependent. RS of grade 1 and grade 2 tumors were significantly lower than grade 3 tumors. There was no high-risk grade 1 tumor. In favorable histologic subtypes there was no high-risk tumor. Mean RS of grade 1 lobular tumors was significantly higher than grade 1 ductal tumors. Using newer ODx cut-offs, 5 grade 1 tumors were reclassified as high risk (RS > 25) and grade 3 lobular tumors showed significantly higher rate of reclassification as high-risk than grade 3 ductal tumors. In a multivariate analysis, only grade showed a significant positive correlation with RS. Adding dichotomous histologic subtyping (favorable vs. non-favorable) to grade further improved correlation with RS.
CONCLUSIONS: The Oncotype Dx result is impacted by histologic grade and histologic subtype. Tumors with favorable histologic subtypes and histologic grade 1 tumors do not have high-risk RS. High RS in a grade 1 tumor or in a tumor with favorable histology is unusual that warrants further investigation. Invasive lobular carcinomas rarely show high-risk RS. Histologic grade and histologic subtype should be considered while ordering ODx testing.

Entities:  

Keywords:  Breast cancer; Chemotherapy; Ductal carcinoma; Genetics; Lobular carcinoma; Prognosis; Recurrence score; Survival

Mesh:

Substances:

Year:  2017        PMID: 29230662     DOI: 10.1007/s10549-017-4619-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

1.  Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.

Authors:  Jing Yu; Jiayi Wu; Ou Huang; Jianrong He; Li Zhu; Weiguo Chen; Yafen Li; Xiaosong Chen; Kunwei Shen
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

2.  Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.

Authors:  Thi Truc Anh Nguyen; Lauren M Postlewait; Chao Zhang; Jane L Meisel; Ruth O'Regan; Sunil Badve; Kevin Kalinsky; Xiaoxian Li
Journal:  Breast Cancer Res Treat       Date:  2022-01-27       Impact factor: 4.872

3.  Development and Validation of an MRI Radiomics-Based Signature to Predict Histological Grade in Patients with Invasive Breast Cancer.

Authors:  Shihui Wang; Yi Wei; Zhouli Li; Jingya Xu; Yunfeng Zhou
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-10-14

4.  Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer.

Authors:  Laura Pons; Laura Hernández-León; Ahmad Altaleb; Esperança Ussene; Roman Iglesias; Ana Castillo; Paula Rodríguez-Martínez; Eva Castella; Vanesa Quiroga; Eudald Felip; Beatriz Cirauqui; Mireia Margelí; Pedro Luis Fernández
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

5.  Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.

Authors:  Jing Yu; Jiayi Wu; Ou Huang; Jianrong He; Li Zhu; Weiguo Chen; Yafen Li; Xiaosong Chen; Kunwei Shen
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

6.  Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.

Authors:  Li Chen; Xiangyi Kong; Zhongzhao Wang; Xiangyu Wang; Yi Fang; Jing Wang
Journal:  J Cell Mol Med       Date:  2020-01-27       Impact factor: 5.310

7.  Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer.

Authors:  Abdulmohsen Alkushi; Ahmad Omair; Haitham Arabi; Emad Masuadi; Omalkhair Abualkhair
Journal:  Breast Cancer (Auckl)       Date:  2020-12-08

8.  Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer.

Authors:  Bader Alshamsan; Aisha Alshibany; Mahmoud A Elshenawy; Ahmed Badran; Tusneem Elhassan; Dahish Ajarim; Adher Alsayed; Kausar Suleman; Taher Al-Tweigeri
Journal:  Cancer Manag Res       Date:  2021-12-29       Impact factor: 3.989

9.  Breast Cancer in the United States: A Cross-Sectional Overview.

Authors:  Nadeem Bilani; Emily C Zabor; Leah Elson; Elizabeth B Elimimian; Zeina Nahleh
Journal:  J Cancer Epidemiol       Date:  2020-10-30

10.  Prognostic Analysis of Primary Breast Signet Ring Cell Carcinoma and Mucinous Breast Adenocarcinoma: A SEER Population-Based Study.

Authors:  Song Wang; Yiyuan Zhang; Fangxu Yin; Xiangsheng Zhang; Zhenlin Yang; Xiaohong Wang
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.